Edgewise Therapeutics, Inc.(EWTX)

POST39.060.000.00%19:30 EDT

39.06-0.17-0.43%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Edgewise Therapeutics (EWTX)
  TIPRANKS · 10-08 23:20
  Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Edgewise Therapeutics (EWTX)
- Edgewise Therapeutics Doses First Patient in Phase 2 EDG-15400 HFpEF Trial
  Reuters · 10-08 20:02
  Edgewise Therapeutics Doses First Patient in Phase 2 EDG-15400 HFpEF Trial
- Edgewise Therapeutics Doses First Patient in Phase 2 Equinox-Hfpef Trial of Edg-15400
  THOMSON REUTERS · 10-08 20:00
  Edgewise Therapeutics Doses First Patient in Phase 2 Equinox-Hfpef Trial of Edg-15400
- Edgewise Therapeutics (EWTX) Could Be 20% Undervalued After Its EDG 7500 Investor Call
  Simply Wall St. · 10-03
  Edgewise Therapeutics (EWTX) Could Be 20% Undervalued After Its EDG 7500 Investor Call
- Edgewise Therapeutics Grants Inducement Equity Awards Covering 11,251 Shares to Three New Employees
  Reuters · 10-01
  Edgewise Therapeutics Grants Inducement Equity Awards Covering 11,251 Shares to Three New Employees
- Edgewise Therapeutics Reports Inducement Grants as Permitted by the NASDAQ Listing Rules
  THOMSON REUTERS · 10-01
  Edgewise Therapeutics Reports Inducement Grants as Permitted by the NASDAQ Listing Rules
- Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says
  MT Newswires Live · 09-26
  Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says
- Edgewise Therapeutics Down over 9%, on Pace for Largest Percent Decrease Since December 2025
  Dow Jones · 09-24
  Edgewise Therapeutics Down over 9%, on Pace for Largest Percent Decrease Since December 2025
- Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says
  MT Newswires Live · 09-23
  Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says
- Edgewise Therapeutics (EWTX) Gets a Buy from RBC Capital
  TIPRANKS · 09-23
  Edgewise Therapeutics (EWTX) Gets a Buy from RBC Capital
- Edgewise Therapeutics Details Preclinical Profile of EDG-7500 Cardiac Sarcomere Modulator in Hypertrophic Cardiomyopathy
  Reuters · 09-22
  Edgewise Therapeutics Details Preclinical Profile of EDG-7500 Cardiac Sarcomere Modulator in Hypertrophic Cardiomyopathy
- Edgewise Therapeutics Price Target Raised to $57.00/Share from $45.00 by HC Wainwright & Co.
  Dow Jones · 09-21
  Edgewise Therapeutics Price Target Raised to $57.00/Share from $45.00 by HC Wainwright & Co.
- US Research Roundup-eBay, Sunbelt Rentals, T-Mobile
  Reuters · 09-21
  US Research Roundup-eBay, Sunbelt Rentals, T-Mobile
- Edgewise Therapeutics Grants Inducement Equity Awards Covering 31,501 Shares to New Hires
  Reuters · 09-02
  Edgewise Therapeutics Grants Inducement Equity Awards Covering 31,501 Shares to New Hires
- Edgewise Therapeutics Reports Inducement Grants as Permitted by the NASDAQ Listing Rules
  THOMSON REUTERS · 09-02
  Edgewise Therapeutics Reports Inducement Grants as Permitted by the NASDAQ Listing Rules
- Goldman Sachs Sticks to Their Hold Rating for Edgewise Therapeutics (EWTX)
  TIPRANKS · 09-01
  Goldman Sachs Sticks to Their Hold Rating for Edgewise Therapeutics (EWTX)
- Edgewise Therapeutics (EWTX) Receives a Buy from RBC Capital
  TIPRANKS · 08-31
  Edgewise Therapeutics (EWTX) Receives a Buy from RBC Capital
- Edgewise Says Phase 2 Cirrus-HCM Trial Shows Positive Top-Line Data for EDG-7500 in Hypertrophic Cardiomyopathy
  Reuters · 08-24
  Edgewise Says Phase 2 Cirrus-HCM Trial Shows Positive Top-Line Data for EDG-7500 in Hypertrophic Cardiomyopathy
- Egetis Bolsters Finances and IP as Emcitate Nears Key FDA Decision
  TIPRANKS · 08-21
  Egetis Bolsters Finances and IP as Emcitate Nears Key FDA Decision
- Edgewise Therapeutics Price Target Raised to $60.00/Share from $53.00 by JP Morgan
  Dow Jones · 08-21
  Edgewise Therapeutics Price Target Raised to $60.00/Share from $53.00 by JP Morgan
Company Profile
Company Name
Edgewise Therapeutics, Inc.
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.edgewisetx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.
- 08-14
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 08-14
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 08-14
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 08-14
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 08-06
  Beneficial Ownership Change
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
- 08-06
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 08-06
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 07-16
  Major Issues Report
  Form 8-K/A - Current report: [Amend]
  Form 8-K/A - Current report: [Amend]
- 07-13
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 07-01
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 06-05
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 06-01
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
- 05-07
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 05-07
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report

1D
5D
Day
Week
Month

Loading ...

High

40.41

Open

39.30

Volume%

0.71

Low

38.93

39.23

T/O Rate

1.21%

To The Moon

Edgewise Therapeutics, Inc.(EWTX)

Company Profile

Most Discussed